• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Orally administered ketoconazole: route of delivery to the human stratum corneum.口服酮康唑:药物送达人体角质层的途径。
Antimicrob Agents Chemother. 1983 Dec;24(6):876-82. doi: 10.1128/AAC.24.6.876.
2
Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum and eccrine sweat.血清、角质层、真皮-表皮(不包括角质层)、毛发、皮脂和外泌汗腺中的特比萘芬水平。
Acta Derm Venereol. 1991;71(4):322-6.
3
Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks.
Acta Derm Venereol. 1993 Aug;73(4):305-9. doi: 10.2340/000155557300304.
4
Pharmacokinetic profile of orally administered itraconazole in human skin.
J Am Acad Dermatol. 1988 Feb;18(2 Pt 1):263-8. doi: 10.1016/s0190-9622(88)70037-7.
5
Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days.每日口服250毫克特比萘芬,持续7天和14天期间及之后,血浆、角质层、真皮-表皮(不包括角质层)、皮脂、毛发和指甲中的特比萘芬水平。
Clin Exp Dermatol. 1994 Mar;19(2):121-6. doi: 10.1111/j.1365-2230.1994.tb01138.x.
6
Levels of fluconazole in serum, stratum corneum, epidermis-dermis (without stratum corneum) and eccrine sweat.血清、角质层、表皮-真皮(不包括角质层)和外泌汗腺中氟康唑的水平。
Clin Exp Dermatol. 1993 Mar;18(2):102-6. doi: 10.1111/j.1365-2230.1993.tb00987.x.
7
Oral ketoconazole in cutaneous fungal infections.
Ann Pharmacother. 1998 Jun;32(6):709-11. doi: 10.1345/aph.18020.
8
Bioavailability of fluconazole in the skin after oral medication.
Mycoses. 1994 Mar-Apr;37(3-4):127-30. doi: 10.1111/j.1439-0507.1994.tb00788.x.
9
Drug testing with alternative matrices I. Pharmacological effects and disposition of cocaine and codeine in plasma, sebum, and stratum corneum.
J Anal Toxicol. 1998 Jan-Feb;22(1):6-17. doi: 10.1093/jat/22.1.6.
10
Intracutaneous transport of orally administered fluconazole to the stratum corneum.口服氟康唑向角质层的皮内转运。
Acta Derm Venereol. 1995 Sep;75(5):361-3. doi: 10.2340/000155557575361363.

引用本文的文献

1
The Effect of Topical Ketoconazole and Topical Miconazole Nitrate in Modulating the Skin Microbiome and Mycobiome of Patients With Tinea Pedis.外用酮康唑和外用硝酸咪康唑对足癣患者皮肤微生物群和真菌群的调节作用。
Mycoses. 2025 Sep;68(9):e70116. doi: 10.1111/myc.70116.
2
Physicochemical properties determining drug detection in skin.决定药物在皮肤中检测的理化性质。
Clin Transl Sci. 2022 Mar;15(3):761-770. doi: 10.1111/cts.13198. Epub 2021 Nov 28.
3
Generalized exfoliative skin rash as an early predictor of supratherapeutic voriconazole trough levels in a leukemic child: A case report.广泛性剥脱性皮炎作为白血病患儿伏立康唑血药谷浓度超治疗范围的早期预测指标:一例报告
Curr Med Mycol. 2020 Sep;6(3):73-78. doi: 10.18502/cmm.6.3.4500.
4
Thermodynamic, Computational Solubility Parameters in Organic Solvents and GastroPlus Based Prediction of Ketoconazole.酮康唑在有机溶剂中的热力学、计算溶解度参数及基于GastroPlus的预测
ACS Omega. 2021 Feb 11;6(7):5033-5045. doi: 10.1021/acsomega.0c06234. eCollection 2021 Feb 23.
5
Antifungal Resistance Regarding : Where Are We Now?关于抗真菌耐药性:我们目前的状况如何?
J Fungi (Basel). 2020 Jun 25;6(2):93. doi: 10.3390/jof6020093.
6
Noninvasive profiling of sweat-derived lipid mediators for cutaneous research.用于皮肤研究的汗液衍生脂质介质的无创分析
Skin Res Technol. 2019 Jan;25(1):3-11. doi: 10.1111/srt.12617. Epub 2018 Jul 21.
7
Oral ibuprofen differentially affects plasma and sweat lipid mediator profiles in healthy adult males.口服布洛芬对健康成年男性的血浆和汗液脂质介质谱有不同影响。
Prostaglandins Other Lipid Mediat. 2018 Jul;137:1-8. doi: 10.1016/j.prostaglandins.2018.05.009. Epub 2018 May 17.
8
Working Up a Good Sweat - The Challenges of Standardising Sweat Collection for Metabolomics Analysis.大汗淋漓——代谢组学分析中标准化汗液采集面临的挑战
Clin Biochem Rev. 2017 Feb;38(1):13-34.
9
Antifungal activity of ketoconazole and other azoles against Malassezia furfur in vitro and in vivo.酮康唑及其他唑类药物对糠秕马拉色菌的体内外抗真菌活性
Infection. 1997 Sep-Oct;25(5):303-6. doi: 10.1007/BF01720401.
10
Treatment and prophylaxis of tinea infections.癣感染的治疗与预防
Drugs. 1996 Aug;52(2):209-24. doi: 10.2165/00003495-199652020-00005.

本文引用的文献

1
Pharmacokinetics of ketoconazole in patients with neoplastic diseases.酮康唑在肿瘤疾病患者中的药代动力学。
Antimicrob Agents Chemother. 1982 Jul;22(1):43-6. doi: 10.1128/AAC.22.1.43.
2
The successful treatment of pityriasis versicolor by systemic ketoconazole.
J Am Acad Dermatol. 1982 Jan;6(1):24-5. doi: 10.1016/s0190-9622(82)80198-9.
3
Ketoconazole in griseofulvin-resistant dermatophytosis.
J Am Acad Dermatol. 1982 Feb;6(2):224-9. doi: 10.1016/s0190-9622(82)70015-5.
4
Determination of the antifungal agent, ketoconazole, in human plasma by high-performance liquid chromatography.
J Chromatogr. 1980 Dec 12;221(2):337-44. doi: 10.1016/s0378-4347(00)84319-4.
5
Oral ketoconazole. An effective and safe treatment for dermatophytosis.
Arch Dermatol. 1981 Mar;117(3):129-34. doi: 10.1001/archderm.117.3.129.
6
Treatment of chronic mucocutaneous candidiasis with ketoconazole: a controlled clinical trial.酮康唑治疗慢性黏膜皮肤念珠菌病:一项对照临床试验。
Ann Intern Med. 1980 Dec;93(6):791-5. doi: 10.7326/0003-4819-93-6-791.
7
Chemical composition of human skin surface lipids from birth to puberty.从出生到青春期人体皮肤表面脂质的化学成分。
J Invest Dermatol. 1970 Feb;54(2):139-44. doi: 10.1111/1523-1747.ep12257164.
8
Griseofulvin levels in stratum corneum. Study after oral administration in man.角质层中的灰黄霉素水平。人体口服给药后的研究。
Arch Dermatol. 1972 Sep;106(3):344-8.
9
Permeability of the skin.皮肤的渗透性。
Physiol Rev. 1971 Oct;51(4):702-47. doi: 10.1152/physrev.1971.51.4.702.
10
Role of sweat in accumulation of orally administered griseofulvin in skin.汗液在口服灰黄霉素于皮肤中蓄积过程中的作用
J Clin Invest. 1974 Jun;53(6):1673-8. doi: 10.1172/JCI107718.

口服酮康唑:药物送达人体角质层的途径。

Orally administered ketoconazole: route of delivery to the human stratum corneum.

作者信息

Harris R, Jones H E, Artis W M

出版信息

Antimicrob Agents Chemother. 1983 Dec;24(6):876-82. doi: 10.1128/AAC.24.6.876.

DOI:10.1128/AAC.24.6.876
PMID:6318663
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC185400/
Abstract

Delivery of ketoconazole to human stratum corneum was studied. Thirteen healthy volunteers, three patients with chronic fungal disease and one patient with palmar-plantar hyperhidrosis were given 400 mg of ketoconazole daily for various lengths of time. The ketoconazole content of palmar stratum corneum, eccrine sweat, sebum, and serum was measured by high-pressure liquid chromatography (sensitivity, 0.005 to 0.010 microgram/ml). Palmar stratum corneum obtained after 7 and 14 days of daily administration contained up to 14 micrograms of ketoconazole per g. Ketoconazole was not found in sebum after 7 or 14 days of daily ingestion of the antimycotic agent. Sebum from three patients with chronic fungal infection treated for greater than 9 months contained ketoconazole (means, 4.7 micrograms/g). Thermogenic whole body eccrine sweat contained a mean of 0.059 microgram/ml on day 7 and 0.084 microgram/ml on day 14 of daily administration. Ketoconazole appeared in thermogenic whole body eccrine sweat and palmar hyperhidrotic sweat within 1 h after a single oral dose. Partition studies of ketoconazole containing eccrine sweat demonstrated a 10-fold greater concentration in the sediment phase (desquamated keratinocytes) compared with the clear supernatant phase. In vitro studies with [3H]ketoconazole-supplemented supernatant sweat revealed preferential binding to stratum corneum, hair, and nails and its partitioning to lipid-rich sebum. We conclude that eccrine sweat rapidly transports ketoconazole across the blood-skin barrier, where it may bind or partition to keratinocytes and surface lipids.

摘要

研究了酮康唑在人角质层中的递送情况。13名健康志愿者、3名慢性真菌病患者和1名掌跖多汗症患者,在不同时间段内每日服用400mg酮康唑。通过高压液相色谱法(灵敏度为0.005至0.010微克/毫升)测量掌部角质层、外泌汗腺汗液、皮脂和血清中的酮康唑含量。每日给药7天和14天后获得的掌部角质层,每克含高达14微克酮康唑。每日摄入抗真菌剂7天或14天后,在皮脂中未发现酮康唑。3名接受治疗超过9个月的慢性真菌感染患者的皮脂中含有酮康唑(平均值为4.7微克/克)。每日给药第7天,产热的全身外泌汗腺汗液中酮康唑平均含量为0.059微克/毫升,第14天为0.084微克/毫升。单次口服给药后1小时内,酮康唑出现在产热的全身外泌汗腺汗液和掌部多汗症汗液中。含酮康唑的外泌汗腺汗液的分配研究表明,沉积物相(脱落的角质形成细胞)中的浓度比清澈的上清液相高10倍。用补充了[3H]酮康唑的上清液汗液进行的体外研究表明,酮康唑优先与角质层、毛发和指甲结合,并分配到富含脂质的皮脂中。我们得出结论,外泌汗腺汗液可迅速将酮康唑转运穿过血-皮屏障,在那里它可能与角质形成细胞和表面脂质结合或分配。